Superficial melanoma, formally called superficial spreading melanoma, is the most common type of skin cancer melanoma. It accounts for roughly 70% to 80% of all melanoma diagnoses. What distinguishes it from other melanoma subtypes is its growth pattern: it spreads outward across the skin’s surface for months or even years before it begins growing deeper into the body. That extended surface-level phase is why it’s called “superficial,” and it’s also what makes early detection so effective.
How Superficial Melanoma Grows
Melanoma starts in melanocytes, the cells that produce skin pigment. In superficial spreading melanoma, abnormal melanocytes first expand horizontally through the top layer of skin (the epidermis). This is called the radial growth phase, and it can last for years. During this time, the lesion gets wider but stays relatively flat and hasn’t yet gained the ability to invade deeper tissue or spread to other parts of the body.
The concern comes when the melanoma transitions into what’s called the vertical growth phase. At that point, cancer cells begin pushing downward into the dermis, the thicker layer beneath the skin’s surface, forming a small nodule. Once that happens, the risk of the cancer reaching lymph nodes or distant organs increases significantly. Research suggests that about 45% of melanomas are caught while still entirely in the radial phase, another 45% have already developed a deeper nodule within that spreading surface lesion, and roughly 10% skip the radial phase altogether and grow straight down from the start.
What It Looks Like
Superficial spreading melanoma typically appears as a flat or slightly raised patch with uneven coloring and jagged, irregular borders. It often contains multiple shades of tan, brown, black, gray, pink, or even blue. Some areas within the lesion may lose pigment entirely, creating lighter spots. Most of these melanomas develop on their own rather than growing from an existing mole.
The ABCDE system is a practical way to evaluate a suspicious spot:
- Asymmetry: one half doesn’t match the other
- Border irregularity: edges are ragged, notched, or blurred
- Color variegation: three or more colors within one lesion
- Diameter: larger than 6 mm (about the size of a pencil eraser)
- Evolution: the spot is changing in size, shape, or color over time
In dermoscopy studies of confirmed superficial spreading melanomas, asymmetry was present in about 85% of cases, three or more colors appeared in 81%, and an irregular pigment network showed up in nearly 80%. Early-stage lesions tend to show subtler patterns, while more advanced ones display a complex, multicomponent appearance under magnification.
Where It Typically Appears
Superficial spreading melanoma shows up most often on areas of skin that get sun intermittently rather than constantly. In both men and women, the trunk is the most common site. Men also develop these lesions relatively often on the head, neck, and upper back, while women see them more frequently on the arms and legs. That said, it can appear anywhere on the body, including areas that rarely see sunlight.
Risk Factors
Ultraviolet radiation is the single biggest environmental driver. An estimated 60% to 70% of all cutaneous melanomas are linked to UV exposure. Childhood sunburns carry particular weight, as UV damage early in life is associated with the specific gene mutations most commonly found in superficial spreading melanoma, especially the BRAF mutation, which appears in about 60% of melanomas overall. Indoor tanning during adolescence or young adulthood also raises risk.
Genetics plays a role too, though a smaller one. Roughly 3% to 15% of melanomas arise from inherited genetic predisposition. Certain rare inherited mutations significantly increase lifetime risk, but for most people, the combination of fair skin, a history of sunburns, and accumulated UV exposure matters more than family history alone.
How It’s Diagnosed
Dermoscopy, a technique where a dermatologist examines the skin through a specialized magnifying instrument, improves diagnostic accuracy by 20% to 30% compared to looking with the naked eye. It helps distinguish melanoma from benign moles by revealing pigment patterns invisible to the unaided eye.
The definitive diagnosis always requires a biopsy, where tissue is removed and examined under a microscope by a pathologist. The biopsy determines whether the melanoma is still confined to the epidermis (called “in situ,” meaning in place) or has begun invading deeper. The depth of invasion, measured in millimeters and known as the Breslow depth, is the single most important factor in determining prognosis and guiding treatment.
Treatment
Surgery is the primary treatment. The goal is to remove the melanoma along with a margin of healthy skin around it to ensure no cancer cells remain. How wide that margin needs to be depends on the tumor’s thickness. For melanoma in situ, the recommended margin is 0.5 to 1 cm of surrounding skin. Thicker melanomas require wider margins. On the head and neck, achieving clear margins can be more challenging due to limited skin, and repeat procedures are sometimes necessary.
For melanomas caught before they’ve grown beyond the skin’s surface, surgery alone is often the only treatment needed. More advanced cases, where the melanoma has grown deeper or reached lymph nodes, may require additional therapies such as immunotherapy or targeted treatments that address specific mutations like BRAF.
Survival Rates and Outlook
The prognosis for superficial spreading melanoma is strongly tied to how early it’s found. According to National Cancer Institute data, 77% of all melanomas are diagnosed while still localized, meaning the cancer hasn’t spread beyond its original site. The five-year survival rate for localized melanoma is effectively 100%.
When melanoma has spread to nearby lymph nodes (regional stage), the five-year survival drops to about 76%. If it has metastasized to distant organs, survival falls to roughly 35%. Because superficial spreading melanoma spends a relatively long time growing outward before it grows downward, it offers a wider window for early detection compared to more aggressive subtypes like nodular melanoma.
Follow-Up After Treatment
Even after successful treatment, ongoing monitoring is important. Between 1% and 8% of melanoma survivors will develop a second, separate melanoma at some point in their lives, though the second one tends to be thinner and caught earlier than the first.
For in situ melanoma, the standard recommendation is annual full-skin exams for life, along with regular self-checks of your skin and lymph nodes. For early-stage invasive melanoma (stages IA through IIA), checkups every 6 to 12 months for the first five years are typical, shifting to annual visits after that. Higher-stage melanomas call for more frequent visits, every 3 to 6 months initially, with imaging scans considered every 4 to 12 months during the first few years to watch for signs of spread. The visit schedule gradually relaxes as time passes without recurrence, since the risk of the cancer returning decreases steadily over the first five years.